A new cancer drug candidate has demonstrated the ability to block tumor growth without triggering a common and debilitating side effect. The compound was developed by Lawrence Livermore National ...
Mutations in the gene encoding PI3Kα are associated with several types of cancer, but selectively targeting oncogenic signalling while leaving physiological PI3Kα activity intact has proved ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback